{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:27:49Z","timestamp":1790263669691,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.numecd.2018.09.006","type":"journal-article","created":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T03:13:03Z","timestamp":1537931583000},"page":"4-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Lipoprotein-X fifty years after its original discovery"],"prefix":"10.1016","volume":"29","author":[{"given":"R.","family":"Fellin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Manzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2018.09.006_bib1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/bs.apha.2015.04.003","article-title":"Bile acid metabolism and signaling in cholestasis, inflammation, and cancer","volume":"74","author":"Li","year":"2015","journal-title":"Adv Pharmacol"},{"key":"10.1016\/j.numecd.2018.09.006_bib2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/jhep.2001.25958","article-title":"Suppression of bile acid synthesis, but not of hepatic cholesterol 7-hydroxylase expression, by obstructive cholestasis in humans","volume":"34","author":"Bertolotti","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2018.09.006_bib3","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/S0022-2275(20)33328-9","article-title":"Serum 27-hydroxycholesterol in patients with primary biliary cirrhosis suggests alteration of cholesterol catabolism to bile acids via the acidic pathway","volume":"39","author":"Del Puppo","year":"1998","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2018.09.006_bib4","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/hep.22771","article-title":"High Expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis","volume":"49","author":"Schaap","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2018.09.006_bib5","doi-asserted-by":"crossref","first-page":"13462","DOI":"10.1038\/srep13462","article-title":"Expression of hepatic fibroblast growth factor 19 is enhanced in primary biliary cirrhosis and correlates with severity of the disease","volume":"5","author":"Wunsch","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.numecd.2018.09.006_bib6","article-title":"Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis","volume":"12","author":"Li","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.numecd.2018.09.006_bib7","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1172\/JCI45277","article-title":"Farnesoid X receptor represses hepatic human APOA gene expression","volume":"121","author":"Chennamsetty","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib8","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1007\/s10620-016-4334-8","article-title":"FXR agonists: from bench to bedside, a guide for clinicians","volume":"61","author":"Alawad","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.numecd.2018.09.006_bib9","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI106085","article-title":"A lipoprotein characterizing obstruction jaundice. I. Method for quantitative separation and identification of lipoproteins in jaundiced subjects","volume":"48","author":"Seidel","year":"1969","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib10","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1172\/JCI106459","article-title":"A lipoprotein characterizing obstructive jaundice. II. Isolation and partial characterization of the protein moieties of low density lipoproteins","volume":"49","author":"Seidel","year":"1970","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1172\/JCI103257","article-title":"Lipoproteins in primary biliary cirrhosis","volume":"35","author":"Russ","year":"1956","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib12","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1172\/JCI105676","article-title":"Plasma lipoproteins in liver disease. I. Immunologically distinct low-density lipoproteins in patients with biliary obstruction","volume":"46","author":"Switzer","year":"1967","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib13","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0021-9258(18)71873-5","article-title":"Isolation, chemical characterization, and biophysical properties of three different abnormal lipoproteins: LP-X1, LP-X2, and LP-X3","volume":"252","author":"Patsch","year":"1977","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2018.09.006_bib14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.172.3982.475","article-title":"Cholestasis: lamellar structure of the abnormal human serum lipoprotein","volume":"172","author":"Hamilton","year":"1971","journal-title":"Science"},{"key":"10.1016\/j.numecd.2018.09.006_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0005-2760(72)90082-3","article-title":"Structure of an abnormal plasma lipoprotein (LP-X) characterizing obstructive jaundice","volume":"260","author":"Seidel","year":"1972","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.numecd.2018.09.006_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1042\/bj1570401","article-title":"Investigation of the abnormal low density lipoproteins occurring in patients with obstructive jaundice","volume":"157","author":"Kostner","year":"1976","journal-title":"Biochem J"},{"key":"10.1016\/j.numecd.2018.09.006_bib17","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/clinchem\/27.6.867","article-title":"High-molecular-mass alkaline phosphatase in serum and bile: nature and relationship with lipoprotein-X","volume":"27","author":"Crofton","year":"1981","journal-title":"Clin Chem"},{"key":"10.1016\/j.numecd.2018.09.006_bib18","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jcla.1860080311","article-title":"Clinical significance of serum high-molecular-mass alkaline phosphatase, alkaline phosphatase-lipoprotein-x complex, and intestinal variant alkaline phosphatase","volume":"8","author":"Wolf","year":"1994","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.numecd.2018.09.006_bib19","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1172\/JCI108393","article-title":"Formation of lipoprotein-X: its relationship to bile compounds","volume":"57","author":"Manzato","year":"1976","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0009-8981(73)90045-4","article-title":"Does lipoprotein-X (LP-X) act as a substrate for the lecithin: cholesterol acyltransferase (LCAT)?","volume":"45","author":"Wengeler","year":"1973","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.numecd.2018.09.006_bib21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/clinchem\/19.1.86","article-title":"Significance of the LP-X test in differential diagnosis of jaundice","volume":"19","author":"Seidel","year":"1973","journal-title":"Clin Chem"},{"key":"10.1016\/j.numecd.2018.09.006_bib22","first-page":"104","article-title":"Correlations between lipoprotein-X and some hepatic enzymes in the diagnosis of cholestasis","volume":"8","author":"Fellin","year":"1976","journal-title":"Rendic Gastroenterol"},{"key":"10.1016\/j.numecd.2018.09.006_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0009-8981(78)90098-0","article-title":"Lipoprotein-X and diagnosis of cholestasis: comparison with other biochemical parameters and liver biopsy","volume":"85","author":"Fellin","year":"1978","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.numecd.2018.09.006_bib24","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/0016-5085(90)90356-6","article-title":"Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis","volume":"98","author":"Rosenson","year":"1990","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2018.09.006_bib25","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jacl.2016.09.016","article-title":"Lipoprotein-X disease in the setting of severe cholestatic hepatobiliary autoimmune disease","volume":"11","author":"Heinl","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2018.09.006_bib26","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0022-2275(20)38428-5","article-title":"Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits","volume":"29","author":"Nordestgaard","year":"1988","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2018.09.006_bib27","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1194\/jlr.M400229-JLR200","article-title":"Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation","volume":"45","author":"Chang","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2018.09.006_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2006.11.036","article-title":"Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review","volume":"94","author":"Sorokin","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2018.09.006_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00365529709025067","article-title":"Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures","volume":"32","author":"Van Dam","year":"1997","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.numecd.2018.09.006_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/gut.51.2.265","article-title":"Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis","volume":"51","author":"Longo","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.numecd.2018.09.006_bib31","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/hep.1840150518","article-title":"Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?","volume":"15","author":"Crippin","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2018.09.006_bib32","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1136\/gut.2005.079814","article-title":"Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis","volume":"55","author":"Allocca","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.numecd.2018.09.006_bib33","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1172\/JCI102222","article-title":"The relationship between serum lipids and skin xanthomata in 18 patients with primary biliary cirrhosis","volume":"28","author":"Ahrens","year":"1949","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0014-5793(73)80511-3","article-title":"Isolation and characterization of lipoprotein-X (LP-X) from canine","volume":"38","author":"Muller","year":"1973","journal-title":"FEBS (Fed Eur Biochem Soc) Lett"},{"key":"10.1016\/j.numecd.2018.09.006_bib35","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1073\/pnas.75.7.3459","article-title":"Secretion of lipoprotein-X by perfused livers of rats with cholestasis","volume":"75","author":"Felker","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.numecd.2018.09.006_bib36","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1172\/JCI3597","article-title":"Class III Pglycoproteins mediate the formation of lipoprotein X in the mouse","volume":"102","author":"Elferink","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2362.1974.tb00415.x","article-title":"Hypertriglyceridaemia secondary to liver disease","volume":"4","author":"Muller","year":"1974","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib38","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1172\/JCI111504","article-title":"Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3- methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat","volume":"74","author":"Walli","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib39","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bbagen.2007.02.010","article-title":"Role of plasma and liver cholesterol- and lipoprotein-metabolism determinants in LpX formation in the mouse","volume":"1770","author":"Bravo","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.numecd.2018.09.006_bib40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2362.1977.tb01646.x","article-title":"Studies on the degradation of lipoprotein-X","volume":"7","author":"Patsch","year":"1977","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib41","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0022-2275(20)39715-7","article-title":"Role of lecithin:cholesterol acyltransferase and apolipoprotein A-I in cholesterol esterification in lipoprotein-X in\u00a0vitro","volume":"36","author":"O","year":"1995","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2018.09.006_bib42","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2362.1979.tb00884.x","article-title":"Lipid deposition in kidneys in experimental liver disease: a study in dogs with choledochocaval anastomosis","volume":"9","author":"Blomhoff","year":"1979","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.numecd.2018.09.006_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150083","article-title":"Lipoprotein X Causes Renal Disease in LCAT Deficiency","volume":"11","author":"Ossoli","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.numecd.2018.09.006_bib44","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.bbalip.2016.04.016","article-title":"Lipid profiling of lipoprotein X: implications for dyslipidemia in cholestasis","volume":"1861","author":"Heimerl","year":"2016","journal-title":"Biochim Biophys Acta"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947531830276X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093947531830276X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:08:45Z","timestamp":1760544525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093947531830276X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S093947531830276X"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2018.09.006","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein-X fifty years after its original discovery","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2018.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}